Pretreatment level of CA 19-9 is a prognostic factor in advanced pancreatic cancer treated with chemotherapy

被引：0
|
作者：
Gansl, R. C. [1 ]
Reis, P. T. [1 ]
Tabacof, J. [1 ]
Simon, S. D. [1 ]
Machado, M. C. [1 ]
Borghesi, G. [1 ]
Saad, E. D. [1 ]
机构：
[1] Dendrix, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.15637
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15637
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CA 19-9 AS A PROGNOSTIC INDEX AFTER RESECTION FOR PANCREATIC-CANCER
    SPERTI, C
    PASQUALI, C
    CATALINI, S
    CAPPELLAZZO, F
    BONADIMANI, B
    BEHBOO, R
    PEDRAZZOLI, S
    JOURNAL OF SURGICAL ONCOLOGY, 1993, 52 (03) : 137 - 141
  • [22] Prognostic impact of presurgical Ca 19-9 level in pancreatic adenocarcinoma: a pooled analysis
    Mattiucci, G. C.
    Arcelli, A.
    Bertini, F.
    Calvo, F. A.
    Falconi, M.
    Farioli, A.
    Guido, A.
    Frezza, G.
    Herman, J. M.
    Miller, R. C.
    Picardi, V.
    Macchia, G.
    Regine, W.
    Reni, M.
    Sharma, N.
    Morganti, A. G.
    Valentini, V.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S53 - S54
  • [23] Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy
    Kim, Yi-Jun
    Koh, Hyeon Kang
    Chie, Eui Kyu
    Oh, Do-Youn
    Bang, Yung-Jue
    Nam, Eun Mi
    Kim, Kyubo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (06) : 1069 - 1075
  • [24] Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy
    Yi-Jun Kim
    Hyeon Kang Koh
    Eui Kyu Chie
    Do-Youn Oh
    Yung-Jue Bang
    Eun Mi Nam
    Kyubo Kim
    International Journal of Clinical Oncology, 2017, 22 : 1069 - 1075
  • [25] Decrease of CA 19-9 in patients with advanced pancreatic cancer (APC) undergoing chemotherapy predicts survival time
    Pohlank, K.
    Hilbig, A.
    Pelzer, U.
    Stieler, J.
    Roll, L.
    Goerke, A.
    Sinn, M.
    Doerken, B.
    Riess, H.
    Oettle, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    Halm U.
    Schumann T.
    Schiefke I.
    Witzigmann H.
    Mössner J.
    Keim V.
    British Journal of Cancer, 2000, 82 (5) : 1013 - 1016
  • [27] Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer
    Stephanie E. Combs
    Daniel Habermehl
    Kerstin A. Kessel
    Frank Bergmann
    Jens Werner
    Patrick Naumann
    Dirk Jäger
    Markus W. Büchler
    Jürgen Debus
    Annals of Surgical Oncology, 2014, 21 : 2801 - 2807
  • [28] Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer
    Combs, Stephanie E.
    Habermehl, Daniel
    Kessel, Kerstin A.
    Bergmann, Frank
    Werner, Jens
    Naumann, Patrick
    Jaeger, Dirk
    Buechler, Markus W.
    Debus, Juergen
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (08) : 2801 - 2807
  • [29] CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy
    Heilbrun, L. K.
    Khanna, A.
    Venkatramanamoorthy, R.
    Shields, A. F.
    Philip, P. A.
    Zalupski, M. M.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    Halm, U
    Schumann, T
    Schiefke, I
    Witzigmann, H
    Mössner, J
    Keim, V
    BRITISH JOURNAL OF CANCER, 2000, 82 (05) : 1013 - 1016
12345